Back to search results

Study Comparing Two Formulations of GSK5784283 for Asthma

This study is comparing two different versions (formulations) of a medicine called GSK5784283. The main goal is to understand how your body processes each version of GSK5784283 over time, and to see if they are safe, well-tolerated, and work in the same way. We are looking for healthy adults between 18 and 60 years old who weigh at least 110 pounds and have a healthy body mass index. This study will enroll 24 participants. The success of the study will be measured by how much GSK5784283 is in your blood at different times after taking the medicine. The current status of this study is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 24 healthy adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels of GSK5784283 will be measured for up to 253 days after you receive the medicine.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07712393

A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283

Recruiting
PHASE1Ages 18–60InterventionalTreatment
GlaxoSmithKline
~24 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:GSK5784283

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Observed Concentration (Cmax) of GSK5784283 Serum Samples
Measured over Pre-dose and up to 253 days post dose
+1 more outcome measured

Conditions

Asthma

Explore related trials

Healthy Volunteers

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • GSK Clinical Trials · STUDY_DIRECTOR · GlaxoSmithKline

Who to contact

US GSK Clinical Trials Call Center
[email protected]
877-379-3718
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG.
Body weight greater than or equal (\>=) 50 kilogram (kg) (110 pounds \[lbs\]) and body mass index within the range 19 to 30 kilogram per meter square (kg/m\^2) (inclusive).
A female participant is eligible to participate if she is a participant of non-childbearing potential (PONCBP) as specified in the protocol.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion

Hypersensitivity- Participants with allergy/intolerance to any biologic therapy or any of the known excipients used in products administered subcutaneously
History or presence of any clinically significant medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs during screening period which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study.
Live vaccine(s) within 1 month prior to screening or plans to receive such vaccines during the clinical study.
Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to study intervention administration.
Current smokers (tobacco and/or marijuana) or former smokers with a smoking history \>10 pack-years and participants using vaping products, including electronic cigarettes.
Regular alcohol consumption that exceeds the limits specified in the protocol
Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the clinical study.
The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine-read or manually over-read \>450 millisecond (msec).

What this trial measures

  • Maximum Observed Concentration (Cmax) of GSK5784283 Serum SamplesPre-dose and up to 253 days post dose
  • Area Under the Curve from Zero up to 253 Days [AUC(0-253 d)] of GSK5784283 Serum SamplesPre-dose and up to 253 days post dose